Interferon in Systemic Lupus Erythematosus

系统性红斑狼疮中的干扰素

基本信息

  • 批准号:
    7569207
  • 负责人:
  • 金额:
    $ 3.69万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-01-15 至 2009-12-31
  • 项目状态:
    已结题

项目摘要

PROVIDED. Systemic lupus erythematosus (SLE) is an autoimmune disease with significant morbidity due to end organ damage mediated by autoantibodies that target nucleic acid-containing immune complexes, along with inflammatory cells and their products. While important observations related to immune regulation and effector mechanisms in SLE have suggested some therapeutic approaches to inhibit autoantibody production and abrogate tissue damage, it would be highly desirable to intervene at the afferent stage of SLE, when autoimmunity is developing. Unfortunately, less information is available regarding these early events. Recent data have documented prominent overexpression of mRNAs encoded by genes regulated by interferons (IFNs) in peripheral blood mononuclear cells from lupus patients. In view of the pleiotropic effects of IFNs on diverse aspects of immune function, many of which could contribute to generation of autoimmunity and inflammation, it would be of high importance to determine the upstream triggers and intracellular pathways that account for activation of the type I IFN (IFN-a) target genes in SLE. In that regard, our data indicate a potential role for RNA in the activation of the IFN pathway in SLE patients. The proposed research will focus on an analysis of the triggers and pathways that account for the increased expression of IFN-a and its downstream target genes. The research will address the hypothesis that activation of gene expression through an RNA-dependent Toll-like receptor (TLR) pathway is an important mechanism of IFN pathway activation, and altered immune system activation, in SLE. The specific aims are: 1) To identify the TLR pathways that mediate IFN expression in SLE; 2) To study the stimuli for TLR pathway activation in SLE; 3) To characterize the downstream targets of TLR pathway activation in SLE; and 4) To study the response of SLE lymphocytes to IFN. Elucidation of this important pathway should lead to more targeted modulation of disease mediators in systemic autoimmune diseases.
提供了 系统性红斑狼疮(SLE)是一种自身免疫性疾病, 由靶向含核酸免疫复合物的自身抗体介导的损伤,沿着 炎症细胞及其产物。虽然重要的观察结果涉及免疫调节和 SLE的效应机制提示了一些抑制自身抗体的治疗方法 产生和消除组织损伤,这将是非常可取的干预传入阶段的 SLE,当自身免疫发生时。不幸的是,关于这些早期的信息较少。 事件最近的数据已经证明了显著的过表达的mRNA编码的基因调控, 干扰素(IFN)的外周血单个核细胞从狼疮患者。鉴于多效性效应 IFN对免疫功能的各个方面的影响,其中许多可能有助于产生 自身免疫和炎症,这将是非常重要的,以确定上游触发, 说明SLE中I型IFN(IFN-a)靶基因活化的细胞内途径。在这方面, 我们的数据表明RNA在SLE患者IFN途径的激活中具有潜在的作用。拟议 研究将侧重于分析导致基因表达增加的触发因素和途径, IFN-α及其下游靶基因。这项研究将解决基因激活的假设, 通过RNA依赖性Toll样受体(TLR)途径表达是IFN-γ的重要机制。 通路激活和改变的免疫系统激活。具体目标是:1)识别 TLR通路介导SLE IFN的表达; 2)研究SLE中TLR通路激活的刺激因素, SLE; 3)表征SLE中TLR通路激活的下游靶点;和4)研究TLR通路激活的下游靶点。 SLE淋巴细胞对IFN的应答。阐明这一重要途径将导致更有针对性的 系统性自身免疫疾病中疾病介质的调节。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Mary K Crow其他文献

Effect of Human Granulocyte Colony Stimulating Factor (rhG-CSF) on Cytokines in VLBW Neonates • 1044
人粒细胞集落刺激因子(rhG-CSF)对极低出生体重儿细胞因子的影响•1044
  • DOI:
    10.1203/00006450-199804001-01065
  • 发表时间:
    1998-04-01
  • 期刊:
  • 影响因子:
    3.100
  • 作者:
    Prabhakar Kocherlakota;Radhakrishna Vakkalanka;Mary K Crow;Edmund F LaGamma
  • 通讯作者:
    Edmund F LaGamma
2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice
2022 年欧洲抗风湿病联盟在临床研究和实践中关于 IFN-I 通路激活测定的测量、报告和应用的要点
  • DOI:
    10.1136/ard-2022-223628
  • 发表时间:
    2023-06-01
  • 期刊:
  • 影响因子:
    20.600
  • 作者:
    Javier Rodríguez-Carrio;Agata Burska;Philip G Conaghan;Willem A Dik;Robert Biesen;Maija-Leena Eloranta;Giulio Cavalli;Marianne Visser;Dimitrios T Boumpas;George Bertsias;Marie Wahren-Herlenius;Jan Rehwinkel;Marie-Louise Frémond;Mary K Crow;Lars Rönnblom;Marjan A Versnel;Edward M Vital
  • 通讯作者:
    Edward M Vital
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023
风湿病领域未满足的需求:2023年靶向治疗进展会议报告
  • DOI:
    10.1136/ard-2023-224916
  • 发表时间:
    2024-04-01
  • 期刊:
  • 影响因子:
    20.600
  • 作者:
    Kevin L Winthrop;Philip Mease;Andreas Kerschbaumer;Reinhard E Voll;Ferdinand C Breedveld;Josef S Smolen;Jacques-Eric Gottenberg;Xenofon Baraliakos;Hans P Kiener;Daniel Aletaha;John D Isaacs;Maya H Buch;Mary K Crow;Jonathan Kay;Leslie Crofford;Ronald F van Vollenhoven;Caroline Ospelt;Stefan Siebert;Margreet Kloppenburg;Iain B McInnes;Ellen M Gravallese
  • 通讯作者:
    Ellen M Gravallese
Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets
系统性红斑狼疮的发病机制:风险、机制和治疗靶点
  • DOI:
    10.1136/ard-2022-223741
  • 发表时间:
    2023-08-01
  • 期刊:
  • 影响因子:
    20.600
  • 作者:
    Mary K Crow
  • 通讯作者:
    Mary K Crow

Mary K Crow的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Mary K Crow', 18)}}的其他基金

Interferon in Systemic Lupus Erythematosus
系统性红斑狼疮中的干扰素
  • 批准号:
    7548595
  • 财政年份:
    2006
  • 资助金额:
    $ 3.69万
  • 项目类别:
Interferon in Systemic Lupus Erythematosus
系统性红斑狼疮中的干扰素
  • 批准号:
    7033222
  • 财政年份:
    2006
  • 资助金额:
    $ 3.69万
  • 项目类别:
Interferon in Systemic Lupus Erythematosus
系统性红斑狼疮中的干扰素
  • 批准号:
    7334208
  • 财政年份:
    2006
  • 资助金额:
    $ 3.69万
  • 项目类别:
Interferon in Systemic Lupus Erythematosus
系统性红斑狼疮中的干扰素
  • 批准号:
    7752864
  • 财政年份:
    2006
  • 资助金额:
    $ 3.69万
  • 项目类别:
Interferon in Systemic Lupus Erythematosus
系统性红斑狼疮中的干扰素
  • 批准号:
    7168015
  • 财政年份:
    2006
  • 资助金额:
    $ 3.69万
  • 项目类别:
Fourth Biennial Arthritis Research Conference
第四届两年一度的关节炎研究会议
  • 批准号:
    6672305
  • 财政年份:
    2003
  • 资助金额:
    $ 3.69万
  • 项目类别:
Premature Atherosclerosis in Rheumatic Diseases
风湿性疾病中的过早动脉粥样硬化
  • 批准号:
    6805632
  • 财政年份:
    2003
  • 资助金额:
    $ 3.69万
  • 项目类别:
Premature Atherosclerosis in Rheumatic Diseases
风湿性疾病中的过早动脉粥样硬化
  • 批准号:
    6734069
  • 财政年份:
    2003
  • 资助金额:
    $ 3.69万
  • 项目类别:
Identification of Rheumatic Disease Genes
风湿病基因的鉴定
  • 批准号:
    6804735
  • 财政年份:
    2003
  • 资助金额:
    $ 3.69万
  • 项目类别:
Premature Atherosclerosis in Rheumatic Diseases
风湿性疾病中的过早动脉粥样硬化
  • 批准号:
    7089925
  • 财政年份:
    2003
  • 资助金额:
    $ 3.69万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 3.69万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 3.69万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 3.69万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 3.69万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 3.69万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 3.69万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 3.69万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 3.69万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 3.69万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 3.69万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了